In the first half of 2025, multinational pharmaceutical companies such as Johnson & Johnson, Roche, AstraZeneca, and Novartis successively announced their performance.
PharmResearch NetworkReply "2025Pharmaceutical companiesFinancial Report"Can be obtained after filling in"MultipleMultinational pharmaceutical companies2025 Q2&H1 Financial Report Package

Johnson & Johnson

• Johnson & Johnson 2025 H1 Performance: Revenue Reaches $45.636 BillionYear-on-year growth4.1%; includingTotal sales reached $23.7 billion in Q2 2025.SameAn increase of 5.8%. In terms of business highlights, the innovative drug segment became the main growth engine, especiallyOutstanding Performance in Oncology Business, with an income of 11.99 billion US dollars in the first half of the year, increasing by 21.1% year-on-year

• Johnson & Johnson Raises Full-Year Guidance Based on Strong Performance, with full-year operational revenue expected to be between USD 93.2-93.6 billion, representing a growth range of 2.5% to 5%.；CFO Says Capable of More M&A

• Johnson & Johnson's stock price has outperformed the industry average year-to-date.Up 17.6% year-to-date.
  

Image Source: Zacks Investment Research

AstraZeneca

• H1 and Q2 2025 Earnings Report:Total revenue was US$28.045 billion, representing a year-on-year increase.11%(Calculated by CER);Core EPS reached $4.66, a year-over-year increase of 17%.The strong growth momentum continues,
  

• AstraZeneca announces the next phase of its growth plan,Will invest $50 billion in the U.S. by 2030 to expand drug manufacturing and R&D capacity.Support AstraZeneca in achieving its goal of reaching $80 billion in revenue by 2030 (half of which will come from the U.S. market).。Under the Shadow of Tariffs, AstraZeneca Makes a $50 Billion Bet on the U.S.

Merck & Co.

• Due to a sharp decline in HPV vaccine sales (Gardasil) in ChinaMerck's total revenue in the first half of the year was $31.335 billion, a year-on-yearDown by 2%Merck's pharmaceutical business revenue was $27.688 billion, a year-on-year decrease of 3%. Among this, due to a sharp decline in HPV vaccine sales (Gardasil), revenue in China fell by 70% year-on-year to $1.075 billion, accounting for 3.9% of Merck's global pharmaceutical business.
  

• Keytruda Sales Still Grow by 7%; Full-Year Sales Target Remains Unchanged at $64.3–65.3 Billion.Merck & Co. to Cut 6,000 Jobs Globally!

Novartis

• 2025 Q2&H1Financial reports show:Sales in the first half of the year were $27.287 billion，Year-on-year growth12%，Core operating revenue reached 11.5 billion yuan, representing a year-on-year increase of 21%.Revenue in China reached $2.2 billion, representing an 8% increase year-over-year.

• Looking ahead to 2025, Novartis expects overall performance to achieve high single-digit growth.。

• Announcement for 2025 H1:Revenue of 15.502 billion pounds (approximately 20.64 billion US dollars, based on the latest exchange rate) increased year-on-year.5%。Core pharmaceuticals business performed outstandingly, with core EPS growing approximately 15%, and strong performance in HIV and oncology sectors;

• GSK in the second quarterAdjustmentPart of the pipeline, successively terminated the development of TIGIT monoclonal antibody belrestotug in non-small cell lung cancer (NSCLC), as well as the Phase III study of antifungal drug ibrexafungerp.GSK Releases H1 "Report Card": Revenue Breaks 20 Billion, Terminates Phase III Projects Including TIGIT Antibody

• GSK Maintains Full-Year Revenue Growth Forecast at 3% to 5%

RaceSanofi

• 2025 Q2&H1The financial report shows:Total revenue in the first half of the year was 19.889 billion euros（Approximately 214.00Billion USD, based on the latest exchange rate），SalesSale IncreaseLong10.1%(CER), where Q2Sales of nine newly launched drugs and vaccines increased by 47.3%.

• Based on the strong sales performance in the first half of the year, the company has adjusted its sales forecast for 2025 to the upper limit of the previous expectation.High single digitsPercentage growth (CER).

AbbVie

• H1 2025 Earnings Report:Total revenue was approximately US$28.766 billion, a year-on-year increase.7.4%，Mainly due to the leading drug Skyrizi in the field of autoimmune diseases (78.48Billion USD,+65.8%)And Rinvoq(37.46Billion USD,+48.5%)The push. The fields of oncology and neuroscience also showed steady growth and strategic expansion.

• AbbVie Raises Full-Year 2025 Profit Forecast

Pharmaceutical Research NetworkReply "2025Pharmaceutical enterprisesFinancial Report"Can be obtained after filling in"MultipleMultinational pharmaceutical companies2025 Q2&H1 Earnings Report Package

End

---

Statement:All articles published on this official account (including original and reprinted articles) are intended to convey more information, and the source and author are credited. This official account welcomes sharing in friend circles or large groups.Unauthorized reproduction by any media or organization in any form to other platforms is prohibited.。

Reprint/Business/Contribution| Contact WeChat15618157102（sum_Gmi）

Business Cooperation

Call for Papers

Click to learn more